Business Context and Reporting Period
This Form 8-K was filed by India Globalization Capital, Inc. (noted as IGC Pharma, Inc. in request metadata) on February 24, 2016. The report details an unregistered sale of equity securities that closed on the same date.
Key Financial Metrics
- Capital Raised: $600,000 total purchase price.
- Shares Issued: 2,142,856 shares of common stock.
- Post-Transaction Outstanding Shares: Approximately 21,108,363 shares.
- Implied Price Per Share: Approximately $0.28 (calculated from total price and share count).
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational or balance sheet metrics.
Material Changes
The primary material change is the increase in outstanding common stock by 2,142,856 shares following the closing of the Q4 2016 Stock Purchase Agreement. The transaction was conducted with unaffiliated purchasers and relied on the Section 4(a)(2) exemption of the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the anticipated closing of the offering, which has now occurred. Management directs investors to the company's Form 10-K and Form 10-Q filings for a detailed discussion of risks and uncertainties. No specific financial guidance or outlook for future periods is provided in this document.
Investor Verification Checklist
- Verify the final share count and ownership structure post-issuance.
- Review the attached Q4 2016 Stock Purchase Agreement (Exhibit 10.1) for specific terms and conditions.
- Confirm the use of proceeds from the $600,000 capital raise in subsequent filings.
- Check the press release (Exhibit 99.1) for additional context on the investors.